Tuesday, July 15, 2014 8:45:09 PM
It is very, very, very hard to launch and sustain a product like this; high risk, high cost, unproven metrics, additional surgical training, duplication with existing methods, etc., etc.. daVinci was in many ways lucky, but had no competition. Titan has entrenched competition; it's called da Vinci. And ISRG has the resources to change the playing field any way they want to, even pricing. People will not flock to SPORT, FOR ONE PROCEDURE.
Titan needs to be developing, at least in theory, where it will evolve even as it launches. Doing the detail work in secret is fine, but the medical amd investment sphere need to have something to pin a future use(s) onto.
I've seen and been involved with potential medical products developed by the finest doctors, medical centers, tech transfer departments, and universities - only to flounder because the market had no friggin' idea what they would be good for.
Just a warning: Titan needs to promote its purpose, or just wind up as a takeover technology. Fine by me if the price is good.
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM